This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ATDBio | |
|---|---|
| Name | ATDBio |
| Type | Private |
| Industry | Biotechnology |
| Founded | 2013 |
| Headquarters | Cambridge, United Kingdom |
| Key people | Adam Zawadzki |
| Products | Functionalized macromolecules, custom conjugation, oligonucleotide labeling |
ATDBio
ATDBio is a biotechnology company based in Cambridge, United Kingdom, specializing in the development and supply of custom functionalized macromolecules, conjugation services, and labeling reagents for life science research and diagnostics. The company serves academic laboratories, pharmaceutical firms, and biotechnology enterprises by providing bespoke chemical modification of proteins, nucleic acids, and polymers. ATDBio's offerings are positioned to support translational research, assay development, and advanced imaging across disciplines linked to molecular biology and biomedical engineering.
ATDBio was founded in 2013 in the biotechnology cluster of Cambridge, joining a regional ecosystem that includes institutions such as the University of Cambridge, the Wellcome Trust Sanger Institute, and the Babraham Institute. Early activity coincided with increased commercial demand driven by research programs at organizations like AstraZeneca, GlaxoSmithKline, and the Francis Crick Institute. ATDBio developed from partnerships with academic groups linked to Cambridge Biocluster initiatives and drew talent with backgrounds from companies such as Illumina, Thermo Fisher Scientific, and Oxford Nanopore. Over its formative years the firm expanded capabilities in chemical conjugation, polymer chemistry, and oligonucleotide modification, aligning with trends exemplified by CRISPR-related projects at the Broad Institute and gene therapy efforts at the National Institutes of Health.
ATDBio's catalog and custom services include chemically functionalized oligonucleotides, modified peptides, protein conjugation, and surface functionalization chemistries used in platforms akin to those from Agilent Technologies and Bio-Rad Laboratories. Product offerings mirror needs in fluorescence microscopy used at institutions like the Max Planck Institute and microscopy hardware from Nikon and ZEISS. Service lines provide bespoke conjugation workflows compatible with antibody suppliers such as Abcam and BioLegend, and labeling solutions useful for single-molecule studies conducted by groups at Harvard University and Stanford University. The company supplies reagents that complement instrumentation produced by PerkinElmer and Bruker for imaging and analytical workflows.
ATDBio's reagents support research programs in areas associated with institutions and initiatives like the European Molecular Biology Laboratory, the Howard Hughes Medical Institute, and the Human Cell Atlas consortium. Applications include probe design for super-resolution microscopy used in labs led by researchers at MIT and Columbia University, oligonucleotide probes for in situ hybridization methods developed alongside groups at the Karolinska Institutet and McGill University, and conjugation chemistries for targeted delivery akin to programs at Moderna and BioNTech. Their products enable assay development compatible with platforms from Roche, Johnson & Johnson, and Merck (MSD) for biomarker detection and translational research in oncology programs at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center.
ATDBio has engaged with academic cores and commercial partners in the Cambridge area and internationally, aligning with consortiums and facilities similar to the European Research Council-funded projects, Wellcome Genome Campus initiatives, and translational partnerships with biotech accelerators such as Cambridge Innovation Capital. Collaborative work often intersects with technology providers like Synthego for genome engineering reagents, Twist Bioscience for oligonucleotide supply chains, and Cytiva for bioprocess tools. Partnerships also facilitate integration with imaging centers at institutions such as King's College London and University College London, and with contract research organizations that serve clients comparable to Janssen and Eli Lilly.
Manufacturing operations emphasize scalable chemical synthesis and quality control practices designed to meet expectations similar to ISO 9001 and pharmacopeial standards relevant for research-use-only reagents. Quality systems reflect workflows and analytical methods employed by organizations such as Thermo Fisher Scientific and Waters Corporation for mass spectrometry and chromatographic validation. Batch release testing and documentation practices accommodate client audits from academic cores, biotechnology firms, and contract manufacturing partners analogous to Catalent and Lonza. Environmental health and safety procedures draw on guidance from agencies and regulatory frameworks in the United Kingdom and European Union.
ATDBio operates within a competitive landscape populated by suppliers like Integrated DNA Technologies, Eurofins Genomics, and Merck KGaA, targeting customers across Europe, North America, and Asia. Market traction has been supported by venture and private funding typical of Cambridge biotech startups and by revenue from custom service contracts with research institutions and small-to-medium biotechnology enterprises. The company benefits from proximity to funding sources such as Innovate UK, venture capital firms active in life sciences, and philanthropic research grants administered by organizations like the Wellcome Trust.
Products are marketed for research use and preclinical applications, aligning with regulatory distinctions upheld by agencies such as the Medicines and Healthcare products Regulatory Agency and the European Medicines Agency. Ethical considerations for use of reagents in human-related studies reflect expectations established by institutional review boards at universities like the University of Cambridge and ethical frameworks promoted by organizations including the Nuffield Council on Bioethics. Compliance with data handling and material transfer agreements follows norms observed by research consortia and innovation partnerships at the Sanger Institute and other major research centers.
Category:Biotechnology companies Category:Companies established in 2013 Category:Companies based in Cambridge